Sermorelin (sermorelin acetate), also known as GRF 1-29, is a peptide that consists of the first 29 amino acids found in naturally occurring growth hormone-releasing hormone (GHRH). Sermorelin is the shortest functioning fragment of GHRH and works as a powerful growth hormone releasing peptide that causes potent growth hormone release . Sermorelin stimulates the release of growth hormone by activating the ghrelin receptor found in the brain. Activating this receptor and increasing the levels of growth hormone within the body can modulate food intake and energy metabolism and also influences glucose and fat metabolism [2, 3]. Growth hormone secretion also increases appetite and causes increased lean muscle growth . Sermorelin can therefore increase lean body mass and muscle during bodybuilding, reduce total and visceral fat and increase bone mass by increasing concentrations of growth hormone and insulin-like growth factor-1 in the body. Sermorelin has been tested in human trials, where the peptide was administered both nasally and intravenously in 30 healthy men. Injection of the peptide, even at the lowest dose tested, led to a significant increase in the release of human growth hormone (HGH), which was maintained for around three hours. Less potent effects were observed via intranasal administration, although there was still a dose-dependent release of HGH . Another benefit found during the study was that sermorelin did not interfere with natural growth hormone release during sleep. The success of sermorelin at releasing growth hormone in healthy men led to it being later tested for treating children with growth hormone deficiencies . This study showed that sermorelin was well tolerated in children and that it promoted growth hormone release and growth in children when given intravenously at 1mcg/kg. Sermorelin is currently used clinically to detect growth hormone deficiencies and to counter the reduction in growth hormones produced as we age. Increasing growth hormone into old age is a potential anti-aging therapy since increasing lean muscle mass can prevent age-associated muscle wasting disorders. Sermorelin has also been shown to improve brain function and can be used to help maintain cognitive function in old age .
The optimal mode of use of the sermorelin peptide is to stack it with low doses of other growth hormone releasing peptides, such as GHRP-2, GHRP-6. Combining a low dose of sermorelin with an additional GHRP will increase the pulse of growth hormone to enhance the peptides benefits. Sermorelin peptide should be reconstituted in BAC water and injected subcutaneously or intramuscularly at a dosage of 200 mcg. The peptide can be dosed once or twice daily and dosages should be spread out over the course of 24 hours.
Sermorelin has been acutely administered to humans at 4 mcg/kg with no serious adverse effects reported. Since sermorelin has been extensively tested and is clinically used then it is considered one of the safest growth hormone stimulating peptides. However, some minor side effects reported in studies include, facial flushing, headache and nausea.
- Kopchick, J.J., E.O. List, and L.A. Frohman, Chapter 20 – Growth Hormone: Structure, Function, and Regulation of Secretion, in Endocrinology: Adult and Pediatric (Seventh Edition), J.L. Jameson, et al., Editors. 2016, W.B. Saunders: Philadelphia. p. 325-358.e14.
- Hosoda, H., M. Kojima, and K. Kangawa, Biological, physiological, and pharmacological aspects of ghrelin. J Pharmacol Sci, 2006. 100(5): p. 398-410.
- Sun, Y., et al., Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci U S A, 2004. 101(13): p. 4679-84.
- Laferrère, B., et al., Growth Hormone Releasing Peptide -2 (GHRP-2), like ghrelin, increases food intake in healthy men. The Journal of clinical endocrinology and metabolism, 2005. 90(2): p. 611-614.
- Wilton, P., et al., Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl, 1993. 388: p. 10-5.
- Prakash, A. and K.L. Goa, Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs, 1999. 12(2): p. 139-57.
- Hersch, E.C. and G.R. Merriam, Growth hormone (GH)–releasing hormone and GH secretagogues in normal aging: Fountain of Youth or Pool of Tantalus? Clinical Interventions in Aging, 2008. 3(1): p. 121-129.